title: Development and evaluation of chitosan and chitosan derivative nanoparticles containing insulin for oral administration.
abstract: Chitosan and chitosan derivative-based nanoparticles loaded with insulin were prepared by self-assembly, via electrostatic interactions between the negatively charged drug and the positively charged polymers. In the investigated chitosan derivatives, the amine groups were substituted to different extents (33, 52 or 99%) by 2-hydroxypropyl-3-trimethyl ammonium groups, rendering the polymers permanently positively charged, irrespective of the pH. This is an important property for this type of advanced drug delivery system, since the pH value changes throughout the gastrointestinal tract and electrostatic interactions are of crucial importance for the stability of the nanoparticles. Permanent positive charges are also in favor of mucoadhesion. In contrast, the electric charges of chitosan molecules depend on the pH of the surrounding medium. Since the solubility of the chitosan derivatives increased due to the introduction of quaternary ammonium groups, sodium tripolyphosphate (TPP) was added to the systems to create supplementary cross-links and stabilize the nanoparticles. The presence of TPP influenced both the dissolution of the polymer matrix as well as the resulting release kinetics. The underlying drug release mechanisms were found to be more complex than simple diffusion under constant conditions, likely involving also ionic interactions and matrix dissolution. The most promising formulation was based on a chitosan derivative with 33% substitution degree and characterized by a Z-average of 142 ± 10 nm, a zeta potential of 29 ± 1 mV, an encapsulation efficacy of 52 ± 3% and, most importantly, the release of insulin was sustained for more than 210 min.
authors.affiliation: a Laboratory of Pharmaceutics and Biopharmaceutics, Université Libre de Bruxelles (ULB) , Campus de la Plaine , Brussels , Belgium and.
authors.forename: J
authors.initials: J
authors.lastname: Hecq
authors.affiliation: b College of Pharmacy, INSERM U 1008, University of Lille , Lille , France.
authors.forename: F
authors.initials: F
authors.lastname: Siepmann
authors.affiliation: b College of Pharmacy, INSERM U 1008, University of Lille , Lille , France.
authors.forename: J
authors.initials: J
authors.lastname: Siepmann
authors.affiliation: a Laboratory of Pharmaceutics and Biopharmaceutics, Université Libre de Bruxelles (ULB) , Campus de la Plaine , Brussels , Belgium and.
authors.forename: K
authors.initials: K
authors.lastname: Amighi
authors.affiliation: a Laboratory of Pharmaceutics and Biopharmaceutics, Université Libre de Bruxelles (ULB) , Campus de la Plaine , Brussels , Belgium and.
authors.forename: J
authors.initials: J
authors.lastname: Goole
mesh_terms: D000284:Administration, Oral; D048271:Chitosan / Q000008:administration & dosage / Q000737:chemistry* / Q000493:pharmacokinetics; D004305:Dose-Response Relationship, Drug; D004337:Drug Carriers / Q000008:administration & dosage / Q000737:chemistry* / Q000493:pharmacokinetics; D004353:Drug Evaluation, Preclinical / Q000379:methods; D006801:Humans; D007328:Insulin / Q000737:chemistry* / Q000493:pharmacokinetics; D053758:Nanoparticles / Q000008:administration & dosage / Q000737:chemistry* / Q000378:metabolism
chemical_list: D004337:Drug Carriers; D007328:Insulin; D048271:Chitosan
keywords: Drug formulation; nanoparticles; oral delivery; peptides; proteins